[Skip to Navigation]
[Skip to Navigation Landing]
Comment & Response
August 2017

Mohs Micrographic Surgery Use in the United States Based on Medicare Data

Author Affiliations
  • 1Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  • 2Florida Center for Dermatology PA, St Augustine
JAMA Dermatol. 2017;153(8):834-835. doi:10.1001/jamadermatol.2017.0732

To the Editor I read with great interest the excellent article by Adamson and Dusetzina1 published in the January 2017 issue of JAMA Dermatology.1 The authors note that 55% of surgically treated nonmelanoma skin cancers were treated with Mohs micrographic surgery (MMS), while excisions and electrodessication and curettage accounted for 16.2% and 28.8% of procedures, respectively. However, the authors’ suggestions that these numbers are inconsistent with the Appropriate Use Criteria (AUC) for MMS,2 and their implication that these data suggest MMS overuse, merit additional context and comment.